Sandu Pharmaceuticals Stock Plummets to New 52-Week Low at Rs. 40.21

Sandu Pharmaceuticals has reached a new 52-week low, hitting Rs. 40.21 today, November 17, 2025. This marks a significant decline for the microcap company, which has seen its stock price decrease by 24.53% over the past year, contrasting sharply with the Sensex's performance of 9.20% during the same period.
The stock has consistently underperformed against the benchmark, trailing the BSE500 in each of the last three annual periods. Today, Sandu Pharmaceuticals underperformed its sector by 1.61%, with its trading price falling below key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages.

Financial metrics indicate weak long-term fundamental strength, with an average Return on Equity (ROE) of just 3.73%. The company's net sales have grown at an annual rate of 4.69%, while operating profit has increased by 17.92% over the last five years. Additionally, Sandu Pharmaceuticals has a poor EBIT to Interest ratio of 1.92, reflecting challenges in servicing its debt obligations. As the market continues to evolve, Sandu Pharmaceuticals' performance remains a focal point for observers in the pharmaceuticals and biotechnology sector.